Response to: Corticosteroids for mild COVID-19 treatment: opening the floodgates of therapeutic benefits.
作者信息
Goel A, Ray A
机构信息
From the Department of Medicine, All India Institute of Medical Sciences, New Delhi, India.
出版信息
QJM. 2022 Oct 25;115(10):702-703. doi: 10.1093/qjmed/hcab313.
Abstract
摘要
相似文献
1
Response to: Corticosteroids for mild COVID-19 treatment: opening the floodgates of therapeutic benefits.
QJM. 2022 Oct 25;115(10):702-703. doi: 10.1093/qjmed/hcab313.
2
Corticosteroids for mild COVID-19 treatment: opening the floodgates of therapeutic benefits.
QJM. 2022 Oct 25;115(10):701. doi: 10.1093/qjmed/hcab312.
3
Corticosteroids for treating mild COVID-19: opening the floodgates of therapeutic misadventure.
QJM. 2021 Nov 5;114(8):541-542. doi: 10.1093/qjmed/hcab138.
4
Unresolved questions about the treatment of COVID-19 with corticosteroids.
Med Clin (Barc). 2021 Feb 12;156(3):143-144. doi: 10.1016/j.medcli.2020.10.010. Epub 2020 Nov 7.
5
Corticosteroids, mortality and mechanical ventilation in COVID-19.
Br J Community Nurs. 2021 Feb 2;26(2):100-101. doi: 10.12968/bjcn.2021.26.2.100.
6
Corticosteroids and COVID-19: What Could Be the Best Bet in Treating Active Glomerular Diseases in Patients With Concomitant Early COVID-19?
Am J Kidney Dis. 2021 Jan;77(1):154-155. doi: 10.1053/j.ajkd.2020.09.006. Epub 2020 Sep 28.
7
IL-6 antagonists to replace systemic corticosteroids as the preferred anti-inflammatory therapy in patients with COVID-19?
Cytokine. 2022 Jan;149:155730. doi: 10.1016/j.cyto.2021.155730. Epub 2021 Oct 5.
8
When should corticosteroids be used for COVID-19 infection?
Eur Respir J. 2022 Jul 13;60(1). doi: 10.1183/13993003.03222-2021. Print 2022 Jul.
9
[Corticosteroids for nursing home patients with COVID-19].
Tidsskr Nor Laegeforen. 2020 Dec 3;140(1). doi: 10.4045/tidsskr.20.0975. Print 2021 Jan 12.
10
COVID-19 and Corticosteroids: Unfamiliar but Potentially Fatal Infections That Can Arise following Short-Course Steroid Treatment.
Am J Trop Med Hyg. 2021 Jan 6;104(3):790-793. doi: 10.4269/ajtmh.20-1471.
本文引用的文献
1
REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19.
N Engl J Med. 2021 Dec 2;385(23):e81. doi: 10.1056/NEJMoa2108163. Epub 2021 Sep 29.
2
COVID-19-associated subacute invasive pulmonary aspergillosis.
Mycoses. 2022 Jan;65(1):57-64. doi: 10.1111/myc.13369. Epub 2021 Sep 29.
3
Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial.
Lancet. 2021 Sep 4;398(10303):843-855. doi: 10.1016/S0140-6736(21)01744-X. Epub 2021 Aug 10.
4
Steroids use in non-oxygen requiring COVID-19 patients: a systematic review and meta-analysis.
QJM. 2021 Nov 5;114(7):455-463. doi: 10.1093/qjmed/hcab212.
5
Response to: COVID-19-associated mucormycosis and evolving evidence.
QJM. 2022 Jun 7;115(6):422. doi: 10.1093/qjmed/hcab191.
6
Corticosteroids for treating mild COVID-19: opening the floodgates of therapeutic misadventure.
QJM. 2021 Nov 5;114(8):541-542. doi: 10.1093/qjmed/hcab138.
7
Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial.
Lancet Respir Med. 2021 Jul;9(7):763-772. doi: 10.1016/S2213-2600(21)00160-0. Epub 2021 Apr 9.
8
Management of COVID-19 from the pulmonologist's perspective: a narrative review.
Expert Rev Respir Med. 2021 Apr;15(4):519-535. doi: 10.1080/17476348.2021.1853529. Epub 2020 Dec 17.
Zotero 插件